Johns Hopkins Technology Transfer has granted a license for Artificial Immune nanotechnology to NexImmune, a startup company formed in part by Johns Hopkins University School of Medicine faculty members who are also involved in the development of the technology. AIM, which involves engineering artificial cells to stimulate specific immune responses, represents a potentially important advance in the development of immunotherapies for a variety of cancers and other diseases.
To read the full, original article click on this link: Technology for cancer immune therapies licensed to NexImmune : Johns Hopkins University – The Gazette
